PE20040575A1 - Medicamento que comprende bencimidazoles - Google Patents

Medicamento que comprende bencimidazoles

Info

Publication number
PE20040575A1
PE20040575A1 PE2003000611A PE2003000611A PE20040575A1 PE 20040575 A1 PE20040575 A1 PE 20040575A1 PE 2003000611 A PE2003000611 A PE 2003000611A PE 2003000611 A PE2003000611 A PE 2003000611A PE 20040575 A1 PE20040575 A1 PE 20040575A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
refers
carbonyl
medication including
Prior art date
Application number
PE2003000611A
Other languages
English (en)
Inventor
Uwe Ries
Wolfgang Wienen
Uwe Schuhly
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040575A1 publication Critical patent/PE20040575A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE Ar ES FENILENO, NAFTILENO, TIENILENO, ENTRE OTROS; A ES ALQUILENO C1-C3; B ES O, S, METILENO, CARBONILO, ENTRE OTROS; Ra ES R1-CO-CICLOALQUILO C3-C5 (DONDE R1 ES ALCOXI C1-C3, AMINO, ALQUIL C1-C4, ENTRE OTROS), R2-CX-CICLOALQUILO C3-C5 (DONDE R2 ES FENILO, NAFTILO, ALQUIL C1-C3-IMINO, ENTRE OTROS), UN GRUPO ALQUILO C1-C3, ENTRE OTROS; Rb ES H O ALQUILO C1-C3; Rc ES CIANO, AMIDINO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES: (R)-2-(4-AMINOFENILAMINOMETIL)-1-METIL-5-[1-(CARBOXIMETILAMINO)-1-(PIRROLIDINOCARBONIL)-ETIL]-BENCIMIDAZOL. SE REFIERE TAMBIEN A LA PREPARACION DE UN MEDICAMENTO UTIL EN EL TRATAMIENTO DEL SINDROME DE RESPUESTA INFLAMATORIA SISTEMICA (SIRS)
PE2003000611A 2002-06-20 2003-06-18 Medicamento que comprende bencimidazoles PE20040575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10227668A DE10227668A1 (de) 2002-06-20 2002-06-20 Arzneimittel zur Behandlung des systemic inflammatory response syndrome

Publications (1)

Publication Number Publication Date
PE20040575A1 true PE20040575A1 (es) 2004-10-05

Family

ID=29719307

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000611A PE20040575A1 (es) 2002-06-20 2003-06-18 Medicamento que comprende bencimidazoles

Country Status (12)

Country Link
EP (1) EP1517687B1 (es)
JP (1) JP4249128B2 (es)
AR (1) AR041180A1 (es)
AT (1) ATE365038T1 (es)
AU (1) AU2003278945A1 (es)
CA (2) CA2489545A1 (es)
DE (2) DE10227668A1 (es)
ES (1) ES2289305T3 (es)
PE (1) PE20040575A1 (es)
TW (1) TW200407130A (es)
UY (1) UY27857A1 (es)
WO (1) WO2004000310A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5851246B2 (ja) * 2008-12-30 2016-02-03 リグスホスピタルＲｉｇｓｈｏｓｐｉｔａｌｅｔ 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物
CN103403018B (zh) 2010-12-21 2015-08-19 医药公司（莱比锡）有限公司 胰蛋白酶样丝氨酸蛋白酶抑制剂,它们的制备以及作为凝结因子IIa和Xa的选择性抑制剂的用途
CN102659687B (zh) * 2012-03-16 2014-10-08 西南大学 苯并咪唑胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI248435B (en) * 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6407130B1 (en) * 1999-11-10 2002-06-18 Boehringer Ingelheim Pharma Kg Carboxamide-substituted benzimidazoles having tryptase-inhibiting activity
US7196095B2 (en) * 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
WO2003035065A1 (en) * 2001-10-26 2003-05-01 Aventis Pharmaceuticals Inc Benzimidazoles and analogues and their use as protein kinases inhibitors

Also Published As

Publication number Publication date
JP4249128B2 (ja) 2009-04-02
AR041180A1 (es) 2005-05-04
CA2715558A1 (en) 2003-12-31
EP1517687B1 (de) 2007-06-20
DE10227668A1 (de) 2004-01-08
TW200407130A (en) 2004-05-16
ES2289305T3 (es) 2008-02-01
WO2004000310A1 (de) 2003-12-31
EP1517687A1 (de) 2005-03-30
ATE365038T1 (de) 2007-07-15
DE50307521D1 (de) 2007-08-02
CA2489545A1 (en) 2003-12-31
AU2003278945A1 (en) 2004-01-06
JP2006514603A (ja) 2006-05-11
UY27857A1 (es) 2003-12-31

Similar Documents

Publication Publication Date Title
JP2008528469A5 (es)
EA200200446A1 (ru) НОВЫЕ α-АМИНОКИСЛОТНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ
PE20030976A1 (es) Piridinoilpiperidinas como agonistas de 5-ht1f
AR081387A1 (es) Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos.
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20091042A1 (es) Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CR7548A (es) Derivados de triazole como antagonistas del receptor de tachykinin
PE20040608A1 (es) Compuestos de alquino con efecto antagonico de la hcm y medicamentos que los contienen
JP2015510886A5 (es)
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AR052330A1 (es) Derivados de adamantano que comprenden quinoleinas sustituidas
NO20063380L (no) Triazolderivater som vasopressinantagonister
ES2496592T3 (es) Proceso para la preparación de Imatinib y compuestos intermedios del mismo
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
AR054524A1 (es) Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato
ES2314418T3 (es) Derivados de amidas del acido 4-bromo-5-(2-clorobenzoilamino)-1h-pirazol-3-carboxicilico y compuestos relacionados como antagonistas del receptor b1 de bradiquinina para el tratamiento de enfermedades inflamatorias.
PE20060084A1 (es) Hidrocloruro de [4-(5-(aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
DE602005016297D1 (de) Antithrombotische diamide
PE20080835A1 (es) Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a
PE20070355A1 (es) Antagonistas de cgrp seleccionados y procedimientos para su preparacion
PE20061155A1 (es) Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
DE602005025332D1 (de) 4-ä2-(cycloalkylamino)pyrimidin-4-ylü-(phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten
EA200500240A1 (ru) Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal